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Interstitial pneumoniaBackground: Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by inﬂamma-
tion and/or ﬁbrosis of the lungs, varying from idiopathic interstitial pneumonias to secondary variants, including
the ILDs associated to connective tissue diseases (CTDs). In addition, a number of patients are recognized as un-
classiﬁable ILD (U-ILD), because of the inability to reach a deﬁnite diagnosis; some of them show autoimmune
manifestations not fulﬁlling the classiﬁcation criteria of a given CTD. The term interstitial pneumonia with auto-
immune features (IPAF) has been recently proposed for this particular ILD subset.
Methods:Here,we report our experience resulting from the integrated— pneumology/rheumatology— approach
to patients with suspected ILDs or CTDs referred to our university-based Center for the Rare Pulmonary Diseases
and Rheumatology Unit, from January 2009 to June 2015, with particular attention to the above-mentioned
U-ILD, IPAF, and undifferentiated connective tissue disease (UCTD). The comparative analysis of these clinical
variantswas carried out;moreover, the observed ﬁndingswere comparedwith the results of the updated review
of the literature.
Results: After the ﬁrst clinical assessment, the U-ILD were identiﬁed in 50 patients; afterwards, on the basis of
clinico-serological and radiologicalﬁndingsU-ILD groupwas subdivided into 2 subgroups, namelyU-ILDwithout
any clinical extra-thoracic manifestations and/or immunological alterations (15 pts) and IPAF according to the
above-mentioned classiﬁcation criteria (35 pts). Patients with either IPAF or U-ILD were compared with a series
of 52 stable UCTD (disease duration ≥3 years), followed at our Rheumatology Unit. Some important differences
were evidenced among the 3 series of U-ILD, IPAF, andUCTD: ﬁrstly, female genderwasmore frequent in patients
with UCTD (86%) or IPAF (69%) comparedwith U-ILD (60%) or idiopathic pulmonaryﬁbrosis (24%; p=0.001). In
addition, UCTD patients were younger and showed longer disease duration. More interestingly, both UCTD and
IPAF series show a comparable prevalence of various clinical manifestations, with the exception of the interstitial
lung involvement detectable in a very small percentage of UCTD patients.
Concordantly, the review of the literature evidenced two main subsets of U-ILD, one is characterized by isolated
unclassiﬁable interstitial pneumonia and another one composed by subjects with clinically prevalent lung
involvement in the setting of not deﬁnite CTD, the recently proposed IPAF.
Conclusion:We hypothesize that IPAF and UCTD might represent two clinical variants of the same systemic au-
toimmune disorders. The marked difference regarding the prevalence of ILD, which is the clinical hallmark of
IPAF but very rare in UCTD, may at least in part reﬂect a selection bias of patients generally referred to different
specialist centers, i.e. pneumology or rheumatology, according to the presence/absence of clinically dominant
ILD, respectively. Well-integrated, interdisciplinary teams are recommended for the assessment and manage-
ment of these patients in the clinical practice. Finally, the cooperation between multidisciplinary groups withit, Dept of Internal Medicine, University of Modena and Reggio E., Policlinico di Modena, Via del Pozzo, 71, 41100Modena Italy.
Table 1
Clinical assessment of patients with interstitial lung disea
General data Signs/symp
Demograﬁc Arthralgias
Occupational Arthritis
Environmental Morning st
Avocational Puffy ﬁnger
Medication Raynaud's p
Smoking Myalgias
Muscle wea
Rash
Photosensit
Alopecia
Dermatitis
Mechanics'
Gottron's si
Skin ulcers
Oral/genita
Oral drynes
Ocular dryn
Dysphagia
Recurrent f
Weight loss
Serositis
Dyspnoea o
Dry cough
ANA: anti-nuclear antibodies; anti-ENA: anti-extractable n
thetase); ESR: eritrocyte sedimentation rate; CRP: C-reacti
matoid factor; anti-CCP: anti-cyclic citrullinated peptide
antibodies; LAC: lupus anticoagulant; HRCT: high-resoluti
a Past and/or present.
62 C. Ferri et al. / Autoimmunity Reviews 15 (2016) 61–70different experiences may be advisable for a validation study of the proposed nomenclature and classiﬁcation
criteria of these indeﬁnable ILD/CTD variants.
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Interstitial lung diseases (ILDs) represent a heterogeneous group of
clinical conditions characterized by inﬂammation and/or ﬁbrosis of
the lungs; it encompasses a spectrum of different subtypes and
phenotypes [1–3]. In particular, ILDs include idiopathic interstitial
pneumonias, and a number of variants secondary to environmental
and occupational exposures, sarcoidosis, pulmonary Langherans cell
hystiocytosis, lymphangioleiomyomatosis, connective tissue diseases
(CTDs), as well as a miscellanea of less frequent forms such as ILDs
associated with systemic vasculitides, including diffuse alveolar
hemorrhage, eosinophilic pneumonia, etc [1–3]. In addition, various
clinico-pathological studies on ILD patients' series referred at tertiary re-
spiratory units focused on the presence of unclassiﬁable ILD (U-ILD);
this is a newly proposed and poorly deﬁnite entity that seems to repre-
sent 10–15% of the whole ILDs [4–8]. Some inconsistencies in the U-ILD
deﬁnition and the lack of conclusive classiﬁcation criteria represent ases (ILDs).
tomsa
iffness
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kness
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l ulceration
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uclear antigen; (antibodies: anti-Scl-
ve protein; HCV: hepatitis C virus; HB
antibodies; AMA: anti-mitochondria
on computed tomography; PFTs: pulchallenging problem in the clinical practice in term of correct diagnosis
and patients' management [4–8]. Thus, several authors emphasized the
importance of a multidisciplinary approach to the complex of ILDs, in-
cluding U-ILD [4,9,10]. In addition to clinical, radiological, and pathologi-
cal features of lung involvement, the patient's assessment should also
include a clinico-immunological evaluation by expert rheumatologists,
considering the incidence of phenotypes with overlapping features of
both ILDs and systemic autoimmune disorders [4,9,10]. Very recently, a
task force of pulmonologists and rheumatologists was formed to develop
a consensus regarding these difﬁculties; the team of investigators pro-
posed the introduction of a novel entity termed interstitial pneumonia
with autoimmune features (IPAF), alongwhich the preliminary classiﬁca-
tion criteria based on the combination of features from clinical, serologi-
cal, and morphological domains [11]. At our university-based Center for
Rare Lung Diseases (MaRP), a similar multidisciplinary approach have
beendirected at patients referred to our tertiary units because of the pres-
ence of suspected ILDs and/or systemic autoimmune diseases. TheLaboratory
examinations
Instrumental
investigations
First line
ANA ≥1:320 titer Chest HRCT
Anti-ENA PFTs (including DLco)
ESR (N2 times normal)
Abnormal CRP
Routine blood chemistry
Urinalysis
Infections
(HCV, HBV, HIV, EBV)
RF
Second line
Anti-CCP Surgical lung biopsy
Complement C3/C4 Doppler echocardiography
AMA Joint echography
ASMA Nailfold capillaroscopy
ANCA Schirmer's test
Anti-phospholipid Ab/LAC Salivary gland echography
Organ-speciﬁc autoAb Minor salivary gland biopsy
24 h-proteinuria Muscle biopsy
Electromyography
Skin biopsy
70, anti-Ro, anti-La, anti-dsDNA, anti-Smith, anti-RNP, anti-PM-Scl, and/or anti-tRNA syn-
V: hepatitis B virus; HIV: human immudeﬁciency virus; EBV: Epstein-Barr virus; RF: rheu-
l antibodies; ASMA: anti-smooth muscle antibodies; ANCA: antineutrophil cytoplasmic
monary function tests; DLco: diffusion lung capacity for carbon monoxide.
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a variety of disorders, ranging from idiopathic pulmonary ﬁbrosis to ILDs
secondary to other conditions,mainly CTDs,with speciﬁc consideration of
the gray zone of unclassiﬁable disorders. This latter comprises different
phenotypes varying from U-ILD [4–8] or the recently proposed IPAF [11]
to undifferentiated connective tissue disease (UCTD). In the ﬁeld of sys-
temic rheumatic diseases, UCTD represents a challenging entity because
of the discrepancies in the symptom composition among published pa-
tients' series, together with the lack of well-recognized classiﬁcation
criteria [12–24].
Here we report our experience resulting from the integrated —
pneumology/rheumatology — approach to patients with idiopathic
and secondary ILDs, including the above-mentioned IPAF and UCTD, as
well as our attempt to better deﬁne these latter conditions on the
basis of observed ﬁndings and throughout the updated review of the
literature.
1.1. Patients and methods
Since 2009 our multidisciplinary team of the university-based
Center for Rare Pulmonary Diseases (MaRP: Malattie Rare del Polmone)
is cooperating in the classiﬁcation, clinical assessment, andmanagementTable 2
Nomenclature of primary/secondary ILDs and related rheumatic disorders.
Nomenclature Deﬁnition
Pulmonary diseases
ILD (interstitial lung disease) Heterogeneous group of diseases that cause ﬁb
pulmonary parenchyma.
IPF (idiopathic pulmonary ﬁbrosis) Chronic, progressive ﬁbrosing interstitial pneu
occurring primarily in older adults, limited to
the histopathologic and/or radiologic pattern o
U-ILD (unclassiﬁable interstitial lung
disease)
ILD without deﬁnite diagnosis because of inad
discordance between clinico-radiologic and pa
UCTD-ILD (UCTD-UIP/UCTD-NSIP)
(undifferentiated connective tissue
disease-interstitial lung disease)
Patients who meet classiﬁcation criteria for UC
or NSIP pattern).
AIF-ILD (autoimmune featured ILD) Clinical subset of ILD with features of CTD (sig
immunological alterations) that do not meet s
a given autoimmune disease.
IPAF (interstitial pneumonia with
autoimmune features)
Interstitial pneumonia and features (clinical, s
morphological) suggestive of a CTD that do not
criteria for a given autoimmune disease.
Lung dominant CTD (lung dominant
connective tissue disease)
Patient with clinically prevalent interstitial pn
autoimmune features suggestive for underlyin
classiﬁcation criteria for deﬁnite CTD.
CTD-ILD (connective tissue
disease-interstitial lung disease)
ILD in the setting of well deﬁned CTD
Miscellanea Exposure related ILD (occupational, environm
smoking), sarcoidosis, idiopathic ILD (RB-ILD,
(Langherans cell histiocytosis, eosinophilic pn
lymphangioleiomyomatosis)
Rheumatic diseases
CTDs (connective tissue diseases) A group of deﬁnite systemic autoimmune disord
erythematosus, inﬂammatory idiopathic myopath
systemic sclerosis, antiphospholipides syndrome,
disease.
UCTD (undifferentiated CTD) Signs and symptoms suggestive of CTD, but no
deﬁnite CTDs, with serum antinuclear antibod
occasions, clinically present ≥3 years
Incomplete/very early CTD Patient with clinical features suggesting a prod
CTD. For example see VEDOSS criteria for a ver
sclerosis: the presence of Raynaud's phenome
positivity plus disease-speciﬁc autoantibodies
microvascular alterations detected by nailfold
RA (rheumatoid arthritis) Chronic inﬂammatory autoimmune disease ch
tenderness, and destruction of synovial joints,
rheumatoid factor and anti-CCP; possible asso
Miscellanea Systemic vasculitides (including diffuse alveol
spondyloarthropathies, Behçet's disease
UIP: usual interstitial pneumonia; NSIP: Non speciﬁc interstitial pneumonia; VEDOSS: very ear
tibodies; anti-CCP: anti-cyclic citrullinated peptide antibodies.of patients affected by either ILDs, with possible extra-pulmonary
rheumaticmanifestations, or systemic autoimmune disorders potential-
ly complicated by lung involvement. Trained pulmonologists and
rheumatologists are involved in the center, where other specialists, i.e.
radiologists, cardiologists, thoracic surgeon, and pathologists actively
collaborate; the involved specialists have a long-term experience on
clinical aspects and treatment of both ILDs and CTDs, including speciﬁc
diagnostic procedures, especially radiological, histopathological,
and immunological investigations, nailfold capillaroscopy, and joint
echography. All patients referred to our tertiary care center because of
respiratory manifestations of ILDs underwent to a core set of clinico-
serological and laboratory investigations, including therapeutical deci-
sions. The initial patient's assessment is followed by periodical patient's
re-evaluation. Table 1 summarizes the ﬁrst patients' clinical work-up
that includes: a) recording of demographic ﬁndings and speciﬁc pa-
tients' exposures potentially responsible for some variants of secondary
ILDs [1,2]; b) awide panel of signs and symptoms of either lung involve-
ment and possible underling CTDs or rheumatoid arthritis [25–32];
c) laboratory, and d) instrumental investigations, directed at the better
deﬁnition of both lung disease and CTDs [25–37; Table 1]. At the ﬁrst
evaluation all patients underwent to ﬁrst line laboratory and instrumen-
tal investigations, repeated periodically during the follow-up accordingReferences
rosis or inﬂammation of the Ryerson CJ, 2013 [3]
monia of unknown cause,
the lungs, and associated with
f UIP.
Raghu G, 2011 [50]
equate data or major
thologic ﬁndings.
Travis WD, 2013 [2], Skolnik K, 2015 [4]
TD and concomitant ILD (UIP Kinder BW, 2007, 2010 [41,44], Corte TJ, 2012 [38]
ns, symptoms, and/or
peciﬁc classiﬁcation criteria for
Vij R, 2011 [42]
erological, and/or
meet established classiﬁcation
Fischer A, 2015 [11]
eumonia associated to different
g CTD, but not fulﬁlling the
Fischer A, 2010 [45]
Ryerson CJ, 2013 [3]
ental, avocational, medication,
DIP, COP, AIP, LIP), others
eumonia, neuroﬁbromatosis,
Ryerson CJ, 2013 [3], Travis WD, 2013 [2]
ers, mainly systemic lupus
ies, Sjögren's syndrome,
and mixed connective tissue
Van den Hoogen F 2013 [25], Vitali C 2002 [26],
Bohan A 1975 [27,28], Petri M 2012 [29], Miyakis S
2006 [30], Mosca M 1999 [16], Sharp GC 1972 [31]
t fulﬁlling the criteria for any of
ies detected on two different
Mosca M, 1999 [16], Clegg DO 1991 [13], Doria A
2005 [20]
romic or very early stage of
y early diagnosis of systemic
non, puffy ﬁngers, and ANA
(ACA, anti-Scl70), and/or
videocapillaroscopy.
Matucci-Cerinic M 2009 [46], Avouac J 2011 [47]
aracterized by swelling,
frequent seropositivity for
ciation with ILD (mainly UIP).
Aletaha D, 2010 [32]
ar hemorrhage syndrome), Ryerson CJ, 2013 [3]
ly diagnosis of systemic sclerosis; ANA: anti-nuclear antibodies; ACA: anti-centromere an-
Table 3
Demographic, clinical, and serological features of our patients' series with UCTD, IPAF, and
U-ILD.
a b c
UCTDe IPAF U-ILD a vs c a vs b b vs c
Pts no. 52 Pts no. 35 Pts no. 15 p p p
Demographic features
Females % (F/M) 86% (44/8) 69% (24/11) 60% (9/6) ns ns ns
Pts mean age (yrs SD)b 55 ± 13 63 ± 12 68 ± 8.9 0.001 ns ns
Disease dur (mean yrs
SD)a
12.1 ± 8.4 7.1 ± 3.1 5.3 ± 2.6 0.003 0.009 ns
Follow-up (mean yrs SD) 6.1 ± 4.4 3.9 ± 2.9 3.5 ± 2.2 0.027 0.019 ns
Clinical features
Arthralgias 91.4% 66.7% 57.1% 0.05 0.04 ns
Arthritis 34.3% 12.9% 0% 0.009 ns ns
Morning stiffness 40% 17.8% 0% 0.004 ns ns
Puffy ﬁngers 0% 0% 0% ns ns ns
Myalgias 20% 40.6% 30.4% ns ns ns
Proximal muscle
weakness
0% 0% 0% ns ns ns
Rash 54.3% 23.3% 0% ≤0.001 0.02 ns
Phosensitivity 37.1% 3.7% 0% 0.005 ≤0.001 ns
Alopecia 2.9% 0.0% 0% ns ns ns
Dermatitis 2.9% 3.6% 0% ns ns ns
Mechanics' hand 0% 0% 0% ns ns ns
Gottron's sign 0% 0% 0% ns ns ns
Skin ulcers 2.9% 0% 0% ns ns ns
Oral ulceration 5.7% 0% 0% ns ns ns
Oral dryness 62.9% 48.2% 40% ns ns ns
Ocular dryness 65.7% 45.2% 25% 0.01 ns ns
Dysphagia 19.4% 0% 0% ns 0.01 ns
Recurrent feverc 10.3% 0% 0% ns ns ns
Weight loss 3.6% 2.9% 6.7% ns ns ns
Raynaud's phen. 77.1% 66.7% 0.0% ≤0.001 ns ≤0.001
Serositis 14.3% 15.4% 6.7% ns ns ns
Interstitial lung disease 4% 100% 100% ≤0.001 ≤0.001 ns
Immunological features
ANA ≥1:320 titer 90% 81.3% 0%f ≤0.001 ns ≤0.001
Anti-ENAd 67.6% 31.4% 0% ≤0.001 0.002 ≤0.001
Rheumatoid factor 9.7% 14.3% 0% ns ns ns
Anti-CCP 15.4% 0% 0% ns ns ns
Low-complement 11.8% 7.6% 0% ns ns ns
UCTD: undifferentiated connective tissue diseases; IPAF: interstitial pneumonia with
autoimmune features; U-ILD: unclassiﬁable interstitial lung diseases; Dis Dur: disease
duration; ANA: anti-nuclear antibodies; anti-ENA: anti-extractable nuclear antigen
antibodies; anti-CCP: anti–cyclic citrullinated peptides.
a From disease onset.
b At the onset of the follow-up.
c Of unexplained origin.
d Anti-Scl-70, anti-Ro, anti-La, anti-dsDNA, anti-Smith, anti-RNP, anti-PM-Scl, or anti-
tRNA synthetase.
e With disease duration ≥3 years.
f 41.7% were ANA-positive but with titer b1:320.
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ratory and extra-pulmonary manifestations were obtained on the basis
of patients' physical examination and speciﬁc questionnaire elaborated
according to guidelines and classiﬁcation criteria of international scien-
tiﬁc societies [25–37; Table 1]. Similarly, laboratory and instrumental in-
vestigations were carried out according to standardized methodologies
[25–38; Table 1].
Given the continuing evolution of proposed ILD subtypes, we report
in the Table 2 the nomenclature, deﬁnition, and classiﬁcation criteria,
when available, of primary and secondary ILDs as well as of CTDs with
correlated ILDs.
1.1.1. Review of the literature
A throughout search in PubMed, Embase, Scopus, Web of Science,
Asian Science Citration Index (ASCI), IranMedex, Scientiﬁc Information
Database (SID), PaKMediNet, IndMed, and Index Medicus for the
World Health Organization EasternMediterranean Region (IMEMR) re-
garding patients with ILDs, CTDs, and CTD-associated ILDs up to August
2015 was done, using the key words lung ﬁbrosis, ILD, IPF, IPAF, UCTD,
and/or CTD.
1.1.2. Statistical analysis
Datawere expressed asmean± standard deviation (SD) unless oth-
erwise noted. Categorical variables were analyzed by chi square test or
Fisher's exact test as appropriate; Wilcoxon test was used to compare
repeated measurements in paired groups, while differences between
the means were determined using Mann–Whitney U-test for unpaired
samples. p values ≤ 0.05 were considered statistically signiﬁcant.
1.2. Results
1.2.1. Our experience
During the last years, from January 2009 to June 2015, at our Center
for Rare Pulmonary Diseases (MaRP)we evaluated a large population of
patients referred because of the presence of signs and symptoms of
suspected ILD.
Besides established— idiopathic and secondary— ILDs, a signiﬁcant
number of U-ILD patients (50 pts) with or without autoimmune fea-
tures was recorded. In U-ILD patients the presence of interstitial pneu-
monia was invariably conﬁrmed by the analysis of imaging features of
high-resolution computed tomography (HRCT) evaluated by trained
pulmonologists and radiologists. A careful analysis of this particular pa-
tients' subset revealed the presence in 26 U-ILD individuals of clinico-
serological autoimmune features not fulﬁlling the classiﬁcation criteria
for a given CTD. These 26 patients were classiﬁed by rheumatologists
as having UCTD according to previously published classiﬁcation criteria
[12,13,16,20]. Following the recent proposal by the task force of
pulmonologists and rheumatologists [11], we re-evaluated our series
of U-ILD patients conﬁrming the presence of IPAF in 35 subjects; this
subset is composed by the above-mentionedUCTD (26 pts) and another
fraction of the former 50U-ILD (9 pts). The Table 3 shows the character-
istics of these two patients' subsets, i.e. 35 IPAF and 15 U-ILD, respec-
tively. The latter 15 patients with true U-ILD were classiﬁed according
to standard criteria [1,2,4], and always in the absence of any clinico-
serological features of autoimmune disease.
Patientswith either IPAF or U-ILDwere comparedwith a series of 52
stable UCTD (disease duration ≥3 years) classiﬁed according current
criteria [12,13,16,20]. The UCTD patients belong to a large series of
various inﬂammatory systemic rheumatic disorders referred to our
Rheumatology Unit and carefully investigated for possible lung involve-
ment. Patients with pulmonary clinico-radiological and/or function
testing alterations were further evaluated and classiﬁed by the MaRP
team. Therefore, a number of important differences can be evidenced
among the3 series of UCTD, IPAF, andU-ILD (Table 3). Firstly, the female
gender is particularly frequent in UCTD (86%) and IPAF (69%), and sta-
tistically signiﬁcant higher compared to our IPF series (24%; p =0.001). In addition, UCTDpatientswere younger and showed longer dis-
ease duration; these differences are more pronounced by comparing
UCTDwith U-ILD. Interestingly, both UCTD and IPAF series show a com-
parable prevalence of various clinical manifestations, with the excep-
tion of the interstitial lung involvement detectable in a very small
percentage of UCTD patients.
1.2.2. Review of the literature
Table 4 summarizes the main reports regarding a number of clinical
investigations [5–8,38–43] and consensus studies with proposals of
classiﬁcation criteria for both U-ILD and UCTD [1,2,11–13,16,20,44,45]:
two clinical entities of uncertain contours and deﬁnition. The U-ILD rep-
resents a heterogeneous number of disorders with clinically prevalent
ILD but without deﬁnite classiﬁcation because of inadequate data or
major discordance between clinico-radiologic and pathologic ﬁndings
[1–3; Table 2]. The clinical and/or classiﬁcation studies included numer-
ically variable patients' series (from23 to 132 pts; ref. 5–8,38–43). Some
Table 4
Review of the literature on U-ILD/IPAF, and UCTD patients' series.
U-ILD Classiﬁcation Clinical studies UCTD Classiﬁcation Clinical studies
Authors, year (ref. no.) studies Pts no. Authors, year (ref. no.) studies Pts no.
Not considering autoimmune features: LeRoy EC, 1980 [12] + −
Xaubet A, 2004 [39] − 26 Clegg DO, 1991 [13] + 410
Morell F, 2008 [40] − 73 Danieli MG, 1999 [14] − 165
Zhang D, 2010 [5] U-ILD 38 Dijkstra S, 1999 [15] − 22
Ryerson CJ, 2013 [6] U-ILD 132 Mosca M, 1999 [16] + −
ATS/ERS, 2002 [1] U-ILD − Cavazzana I, 200 [17] − 148
Travis WD, 2013 [2] U-ILD − Mosca M, 2002 [18] − 64
Hyldgaard C, 2014 [7] − 62 Bodolay E, 2003 [19] − 435
Troy L, 2014 [8] − 23 Doria A, 2005 [20] + −
Vaz CC, 2009 [21] − 184
Considering autoimmune features: Conti V, 2010 [22] − 41
Kinder BW, 2007 [44] UCTD-ILD 28 Guerrero LF, 2013 [23] − 94
Kinder BW, 2010 [41] − 29
Fischer A, 2010 [45] Lung dominant CTD −
Vij R, 2011 [42] AIF-ILD 63
Corte TJ, 2012 [38] − 52
Pan L, 2013 [43] − 65
Fischer A, 2015 [11] IPAF −
Present series UCTD; IPAF, U-ILD 102
ILD: interstitial lung diseases; CTD: connective tissue diseases; U-ILD: unclassiﬁable interstitial lung diseases; UCTD: undifferentiated connective tissue diseases; AIF-ILD: autoimmune
featured interstitial lung diseases; IPAF: interstitial pneumonia with autoimmune features.
65C. Ferri et al. / Autoimmunity Reviews 15 (2016) 61–70reports focused on pulmonary clinico-radiological and pathological fea-
tures with the purpose of better deﬁne the borders and the distinctive
features of U-ILD. Other studies underlined the association of interstitial
pneumonia with a variable number of autoimmune features — clinical
and/or serological — suggesting the presence of systemic immune-
mediated disorder with prevalent lung involvement. In all cases the
presence of autoimmune components was not sufﬁcient to classify the
underlying disorder as deﬁnite CTD. The authors proposed different
terms evidencing the coexistence of unclassiﬁable interstitial lung in-
volvement and undifferentiated autoimmune disorders; namely, ‘auto-
immune featured ILD’, ‘lung dominant CTD’, ‘UCTD-ILD’, or the recently
IPAF (Table 4). Although these terms seem to refer to the same clinical
entity, there are important differences in the composition of patients'
series recruited at various tertiary care centers, in the employed assess-
ment methodologies, and consequently in the proposed classiﬁcation
criteria. However, taken together these previous studies seem to identi-
fy two main subsets of U-ILD, one regarding patients with isolated
unclassiﬁable interstitial pneumonia and another one composed by
subjects with clinically prevalent lung involvement in the setting of
not deﬁnite CTD. This dichotomy seems to be conﬁrmed by the results
of our study showing the presence of two distinct phenotypes of
U-ILD, namely the true U-ILD and the IPAF [11].
On the other hand, published studies in the ﬁeld of autoimmune
rheumatic diseases, focusing on UCTD patients (Table 4), are quite
concordant as regards the deﬁnition and clinical characteristics of this
disorder, including the rarity of clinically overt interstitial lung involve-
ment [16–24]. Patients with stable UCTD show clinical features, lasting
≥3 years, and serological markers suggestive of CTDs but not fulﬁlling
the criteria for any of deﬁnite CTDs. With regards to UCTD classiﬁcation
criteria available data are generally limited to the results of consensus
or expert opinion reports [12,13,16,20] in the absence of validation
studies.
1.2.3. Suggestions for ongoing classiﬁcation criteria
The analysis of previous literature on U-ILD patients' series revealed
a number of proposals for a better deﬁnition and classiﬁcation criteria of
this condition [1–3,5–8,11,38–45]. The termU-ILDwas initially referred
to a patients' subset characterized by interstitial pneumoniawithout ep-
idemiological and clinic-pathological features of deﬁnite ILD [1–3].
Therefore, an increasing number of studies focused on the presence
of a particular U-ILD phenotype associated to one or more clinic-
serological features suggesting a possible underlying autoimmunedisorder [11,38,41–45]. A number of above-mentioned deﬁnitions
have been proposed for this peculiar entity (Tables 2, 4); by adopting
the lastly suggested IPAF, we observed a clear overlapping of clinico-
epidemiological features between IPAF, recruited at our Center for
Rare Pulmonary Diseases, and UCTD patients, referred to our Rheuma-
tology Unit, with the exception of interstitial pneumonia. This impor-
tant difference can be explained at least in part by a selection bias in
the patients' referral: subjects with clinically dominant respiratory
symptoms are invariably referred to tertiary pulmonary care unit,
while patients with a variable composition of autoimmune features
but without or mild/subclinical respiratory symptoms are commonly
referred to rheumatologists (Fig. 1). In this context, the three patients'
series reported in Table 3 constitute a spectrum of undifferentiated/
unclassiﬁable conditions (Fig. 2) that can be observed in the settings
of either ILDs or CTDs, referred to different tertiary centers such as
Pneumology and Rheumatology Units, respectively. From one side
there are patients with U-ILD, a condition characterized by the absence
of environmental exposures or immune-mediated disorders and appar-
ently isolated interstitial pneumonia [1–3], from the opposite side there
are the so-called UCTD with prevalent autoimmune features and rare
lung involvement [12,13,16,20]. While the IPAF that is characterized
by both ILD and autoimmune featuresmay represent a transitional con-
dition between U-ILD and UCTD. Moreover, both IPAF and UCTD could
be classiﬁed in the setting of CTDs, a group of multifaceted autoimmune
disorders with frequent phenotypic variations during the time; conse-
quently, we cannot exclude that in some individuals theymay represent
a prodromic condition or very early phase of a given CTD [46,47]. The
evolution into deﬁnite CTDs is more likely during the ﬁrst years of dis-
ease; at the ﬁrst evaluation or during the follow-up period, it is possible
to identify patients with speciﬁc clinico-serological ﬁndings suggestive
of a given CTD. Therefore, a multidisciplinary clinical assessment and
monitoring may be decisive for the prognostic and therapeutical impli-
cations (Fig. 3). The initial evaluation of IPAF/UCTD patient’s should be
based on a core set of standard clinico-serological and instrumental in-
vestigations in order to detect individuals at risk to develop or with un-
derlying ‘early’ CTDs or other autoimmune systemic rheumatic diseases
(Tab. 1, 5; 48–67). Consequently, second line laboratory/instrumental
investigations should be decided on the basis of speciﬁc clinical aspects
thatmight characterize individual IPAF patients. As example, thosewith
Raynaud's phenomenon and/or puffy ﬁngers, and/or typical serological
markers (anti-Scl70, anticentromere, anti-nucleolar antibodies),
suggesting the presence of early systemic sclerosis, can be further
Fig. 1. At our center for the Rare Pulmonary Diseases there are referred patients with
suspected interstitial lung diseases (ILDs) because of isolated/prevalent respiratory man-
ifestations. They are evaluated by means of wide clinical work-up (Table 1) by trained
pulmonologists and rheumatologists, with the contribution of other specialists, i.e. radiol-
ogists, cardiologists, thoracic surgeon, and pathologists; the involved specialists have a
long-term experience on the diagnosis and treatment of ILDs aswell of CTDs and other au-
toimmune diseases (AIDs) referred to our Rheumatology Unit. Patients were ﬁnally classi-
ﬁed according to guidelines and classiﬁcation criteria of international scientiﬁc societies
(ref. 25–37). Besides established ILDs, CTDs, and AIDs, there are subjects with unclassiﬁ-
able interstitial lung diseases (U-ILD). These latter include a number of patients that fulﬁll
the recently proposed ‘interstitial pneumoniawith autoimmune features’ (IPAF). The IPAF
patients were compared with unclassiﬁable connective tissue diseases (UCTD) recruited
among different CTDs and other AIDs referred to our Rheumatology Unit. There is a
clear-cut clinic-serological overlapping between these two patients' series, with the ex-
ception of ILD detectable in a very small percentage of UCTD patients (see Table 3). This
difference can be correlated to a selection bias in the patients' referral: subjects with
clinically dominant respiratory symptoms are invariably referred to tertiary pulmonary
care unit, while patients with prevalent autoimmune features, with/without respiratory
symptoms, are commonly referred to rheumatologists (see also Fig. 2). *Exposure related
ILD (occupational, environmental, avocational, medication, smoking), sarcoidosis, idio-
pathic ILD [respiratory bronchiolitis-associated-ILD (RB-ILD), desquamative interstitial
pneumonia (DIP), cryptogenic organizing pneumonia (COP), acute interstitial pneumonia
(AIP), lymphocytic interstitial pneumonia (LIP)], others (Langherans cell histiocytosis, eo-
sinophilic pneumonia, neuroﬁbromatosis, lymphangioleiomyomatosis); IPF: idiopathic
pulmonary ﬁbrosis; °other systemic autoimmune diseases (AIDs): see Table 5.
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[35,36,46,47].While patientswith sicca syndromewith/without speciﬁc
autoantibodies (anti-Ro, anti-La) of suspected Sjögren's syndrome may
undergo to Schirmer's test, salivary gland echography, and/orminor sal-
ivary gland biopsy [26]. Finally, subjects with arthritis should be deeply
evaluated for possible rheumatoid arthritis bymeans of speciﬁc serolog-
ical examinations (rheumatoid factor and anti-cyclic citrullinated pep-
tide antibodies), with some limitations [68,69], echographic, and/or x-
ray examinations of inﬂamed joints [32,37].
1.3. Discussion
The present study reports our interdisciplinary experience on the
clinical evaluation of patients with U-ILD. In particular, it focuses onindividuals with concomitant interstitial pneumonia and autoimmune
features, fulﬁlling the recently proposed classiﬁcation criteria for IPAF
[11]; their clinico-serological ﬁndings were also compared with a series
of UCTD patients belonging to a large series of systemic autoimmune
diseases followed at our Rheumatology Unit. In addition, we describe
our model of integrated approach — pneumology/rheumatology —
aiming at a better deﬁnition of these still unclear conditions [2–4,11,
13,16,20,38,42,44,45]. The proposed model was based on our clinical
practice as well as on the data emerging from updated review of the
world literature on this topic (see references in Table 2; 10).
During the last years we evaluated with systematic, multidisciplin-
ary approach a large series of patients with suspected ILDs and/or rheu-
matic autoimmune disorders potentially complicated by pulmonary
manifestations, namely CTDs and AIDs (Table 5). In the setting of
established ILDs, we identiﬁed a group of patients with U-ILD, classiﬁed
according to current criteria [2,4. In particular, we focused on individ-
uals with U-ILD and clinico-immunological manifestations of systemic
autoimmune disorders, but not fulﬁlling the classiﬁcation criteria of a
given disease [2–4,42,44,45; Tables 2, 5]. Moreover, we recently
reclassiﬁed these patients according to the proposed criteria for IPAF
[11]; the comparative analysis of IPAF and stable UCTD, recruited at
our Rheumatology Unit, revealed a clear-cut overlap of clinical symp-
toms and immunological alterations between these two disorders, ex-
cepting the presence of interstitial pneumonia. This latter organ
manifestation represents the main clinical hallmark of IPAF, while it
was rarely observed in our UCTD patients (Table 3), conﬁrming the
data of the previous literature [16–24]. In order to explain this particular
discrepancy, we hypothesize that both IPAF and UCTD may belong to
unique unclassiﬁable systemic autoimmune disorder, but patients are
generally referred to different tertiary care centers, namely Pneumology
or Rheumatology Units, based on the presence/absence of clinically
overt lung involvement, respectively. In this scenario, the IPAF may be
regarded as the bridging condition between the U-ILD without extra-
thoracic manifestations and UCTD; all together these disorders consti-
tute the spectrum of undifferentiated variants of deﬁnite ILDs, CTDs,
and other autoimmune systemic diseases (Fig. 2, Tables 2, 5).
The development of standardized nomenclature and validated classi-
ﬁcation criteria for the U-ILD [2,4] in general, and in particular for patients
with IPAF [11] should be taken into account also the so-called UCTD, a
woolly condition in the ﬁeld of systemic autoimmune rheumatic diseases
still awaiting for a better clinico-prognostic deﬁnition [16–24].
In this respect, a clear clinico-epidemiological overlap between ap-
parently idiopathic interstitial pneumonia with one or more autoim-
mune features of CTDs, classiﬁed according to rheumatologists'
current criteria (Table 5), has been previously underlined by other
authors [38,41,44]. The extent of overlapping area between different
ILDs with suspected underlying autoimmune diseases and UCTD may
vary because of the heterogeneity of adopted classiﬁcation criteria
[10,38,41,44]. A number of terms and classiﬁcation criteria for U-ILD,
mainly for autoimmune ‘ﬂavored’ variants, have been proposed during
the last years (Table 2; 3,11,38,41–45). Often, the suggested deﬁnitions
are referred to limited ILD patients' series and/or expert opinions, with
important differences of methodological approach and/or clinical experi-
ence (Table 2). In order to improve and uniform the current nomencla-
ture and classiﬁcation criteria, well-balanced teams of pulmonologists
and rheumatologists, with the contribution of other specialists, mainly
radiologists and pathologists, should deal with this important topic. As
regards the possible bias of patients pre-selection before the referral to
different tertiary care centers could be avoided by means of assessment
and long-term follow-up of patients with either ILDs and CTDs carried
out by the same multidisciplinary team. In this setting, continual discus-
sion regarding potential clinical phenotypes may allow to early identify
the possible autoimmune features associated to ILDs, from one side, as
well as potential interstitial lung involvement complicating established
CTDs and other autoimmune rheumatic diseases, from the other side
(Fig. 3, Table 5). Moreover, long-term clinical follow up of U-ILD, mainly
Fig. 2. The spectrum of undifferentiated/unclassiﬁable conditions that can be observed in the ﬁeld of interstitial lung diseases (ILDs), connective tissue diseases (CTDs), and other autoim-
mune diseases (AIDs; see Table 5) includes unclassiﬁable interstitial lung diseases (U-ILD), interstitial pneumonia with autoimmune features (IPAF), and unclassiﬁable connective tissue
diseases (UCTD). The IPAFmay represent a transitional phenotype in the middle of U-ILD and the UCTD; IPAF are characterized by the presence of both interstitial lung involvement and
autoimmune features. *Exposure related ILD (occupational, environmental, avocational, medication, smoking), sarcoidosis, idiopathic ILD [respiratory bronchiolitis-associated-ILD
(RB-ILD), desquamative interstitial pneumonia (DIP), cryptogenic organizing pneumonia (COP), acute interstitial pneumonia (AIP), lymphocytic interstitial pneumonia (LIP)], others
(Langherans cell histiocytosis, eosinophilic pneumonia, neuroﬁbromatosis, lymphangioleiomyomatosis); IPF: idiopathic pulmonary ﬁbrosis.
Fig. 3. The ﬁgure summarizes the activity of our multidisciplinary, integrated pneumology–rheumatology center, devoted to patients with idiopathic and secondary interstitial lung dis-
eases (ILDs), with particular attention to ILDs associated to connective tissue diseases (CTDs) or other autoimmune diseases (AIDs, see Table 5). These disorders are characterized bymul-
tifactorial andmultistep etiopathogenesis that can be responsible for theproduction of different phenotypes. Our standardizedmodel takes into account these complex scenario in order to
correctly classify the clinical subtypes and to early detect possible predictive factors of speciﬁc CTD/AID development: 1) Initial assessment and classiﬁcation, according to current criteria,
of patients referred to the Center for Rare Pulmonary Diseases (patients with suspected ILDs) or Rheumatology Unit (patients with suspected CTDs/AIDs) of our university-based hospital.
2) Patientswith established ILDs and CTDs/AIDs, aswell as individualswith unclassiﬁable ILDs (U-ILD), interstitial pneumoniawith autoimmune features (IPAF), and undifferentiated con-
nective tissue diseases (UCTD) were carefullymonitored. 3) Long-term follow-up allows to early observe possible variations of patients' clinico-serological manifestationswith impact on
classiﬁcation/diagnosis. This is particularly important for patients with unclassiﬁable/undifferentiated disorders (U-ILD, IPAF, UCTD); the detection of clinico-serological features suggest-
ing the presence of possible/incomplete or very early disease may be critical to deﬁne emerging speciﬁc phenotypes of ILDs (example: patients with IPF developing a CTD-associated ILD)
or of CTDs/AIDs (example: rare cases of SSc or RA patients originally referredwith apparently isolated ILD as presenting symptom). This approach can be crucial in some cases for targeted
therapeutical decisions, particularly in the very early phase of a given disease (see text, Figs. 1, 2; Tables 1, 3). °Exposure related ILD (occupational, environmental, avocational,medication,
smoking), sarcoidosis, idiopathic ILD [respiratory bronchiolitis-associated-ILD (RB-ILD), desquamative interstitial pneumonia (DIP), cryptogenic organizing pneumonia (COP), acute inter-
stitial pneumonia (AIP), lymphocytic interstitial pneumonia (LIP)], others (Langherans cell histiocytosis, eosinophilic pneumonia, neuroﬁbromatosis, lymphangioleiomyomatosis); IPF:
idiopathic pulmonary ﬁbrosis; SSc: systemic sclerosis; SLE: systemic lupus erythematous; SS: Sjögren's syndrome; DM/PM: dermatomyositis/polymyositis; RA: rheumatoid arthritis;
*other systemic autoimmune diseases (AIDs): see Table 5.
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Table 5
Prevalence of interstitial lung diseases in systemic autoimmune rheumatic diseases.
Diseases ILDs Comment
Classical connective tissue diseases
Systemic sclerosis (SSc) 55–65% [34,48] Clinically overt ILD; mainly in diffuse cutaneous SSc subset [49]; NSIP pattern more frequently reported
[50]
Systemic lupus erythematosus (SLE) 1–15% [51] Mainly in long-lasting disease duration and older patients; possible evolution from SLE pneumonitis [52]
Sjögren's syndrome (SS) 2–45% [53-55] ILD prevalence directly correlated with SS duration [55]
Inﬂammatory myopathies (DM/PM) up to 75% [56] Anti-synthetase antibodies mark the presence/development of ILD [56]
Mixed connective tissue disease 35–66% [57,58]
Undifferentiated connective tissue disease (UCTD) n.a. ILD is not reported in UCTD cohort studies [16-24]
Other systemic autoimmune diseases
Rheumatoid arthritis 4–68% [59] Smoking, male gender, and long-standing disease are frequently reported as risk factors for ILD [59];
UIP pattern present in 2/3 cases [60]
Ankylosing spondylitis 35–65% [61] data from small case series
Behçet's disease n.a. nodular or reticular opacities have been occasionally described and considered residuals of lung
hemorrhage/infarcts [62]
Cryoglobulinemic vasculitis Anecdotal [63] Subclinical lymphocytic alveolitis (BAL) [64,65]
ANCA-associated vasculitidesa ~3 [66] Association with MPO-ANCA antibodies [66]
ILDs: interstitial lung diseases; NSIP: Non Speciﬁc Interstitial Pneumonia; UIP: Usual Interstitial Pneumonia; DM/PM: dermatomyositis/polymyositis; n.a.: not available; BAL: broncho-
alveolar lavage; MPO-ANCA: anti-myeloperoxidase-antineutrophil cytoplasmic autoantibodies.
a Granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis.
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of a given systemic autoimmune disorder in its very early stage (Fig. 3).
This approach can be decisive for early, targeted therapeutical strategy
in the single patient with speciﬁc clinical phenotype. In the clinical prac-
tice, it is possible toﬁnd patientswith presenting ILDwho develop during
the follow-up one or more features of early systemic sclerosis, the CTD
with high prevalence of ILD (Table 5;), or early rheumatoid arthritis,
two pathogenically different conditions needing distinct, speciﬁc treat-
ments (Table 5; 34,48–50). In similar circumstances, the detection of typ-
ical, but often subtle symptoms should be decisive for the early diagnosis,
when pathogenetic treatments may have the highest likelihood to
positively affect the overall disease outcome. Another example may be
the case of a patient with apparently isolated interstitial pneumonia
(UIP pattern) who developed after 12-month follow-up a sensory
neuropathy at the lower limbs due to biopsy-proven vasculitic (p-ANCA
positive) peripheral nerve involvement (personal observation). Longer
clinical follow up of this patient may permit a better disease deﬁnition;
however, such clinical observations underline the needing of careful
patient's long-term monitoring to better classify individuals with appar-
ently ‘idiopathic’ interstitial pneumonia as expression of underlying auto-
immune disorders.
Patients with ILDs, including IPF, may clinically develop with an in-
sidious onset characterized by dyspnea on exertion and bibasilar inspi-
ratory crackles. Therefore, various etiopathogenetic factors, namely
environmental exposures, drug toxicity, or systemic autoimmune
diseases, especially classical CTDs (Table 5), must be considered in
order to correctly classify idiopathic and secondary ILDs [1–3].
Some features can be usefully employed for a correct patient's assess-
ment; in particular, individualswith underlying CTDs aremore frequently
young femalewithmultisystemdisease [48–66]; theymay present one or
more extrathoracic manifestations such as Raynaud phenomenon,
arthralgias/arthritis, sicca syndrome, skin, muscle, and/or mucosal mani-
festations, with serum immunological alterations (Table 1). Moreover,
pulmonary manifestations of patients with ILD-CTD are generally
multicompartmental, showing various degrees of lung, pleura, airway,
pericardium, and/or pulmonary vascular involvement. The clinically het-
erogeneous manifestations of ILD-CTD are mirrored by the pathological
lung patterns, including NSIP, the most prevalent, UIP, lymphocytic
interstitial pneumonitis, cryptogenic organizing pneumonitis, or diffuse
alveolar hemorrhage, as well as the combination of the above patterns
[70]. Classical CTDs, other autoimmune diseases (Table 5), as well as
the associated ILDs, are characterized by multifactorial and multistep
etiopathogenesis. These conditions may clinically manifest with a
variable, often unpredictable symptom composition during the naturalcourse of the disease; therefore, a careful long-termmonitoring is recom-
mendable in all cases.
In this scenario, we agree with the proposal of multidisciplinary ap-
proach by ERS/ATS Task Force [11], with the adoption of the term IPAF
that is more inclusive compared to previous nomenclature (Table 2).
Accordingly, we suggest to cover the complete spectrum of systemic
autoimmune diseases (Table 5) in the clinical work-up and differential
diagnosis of ILD patients with autoimmune and/or rheumatologic
‘ﬂavor’ [11].
Moreover, clinico-serological monitoring of patients with IPAF or
UCTD may allow to deeply investigate speciﬁc pathogenetic mecha-
nisms as well as possible parameters able to predict the evolution to
deﬁnite disease phenotypes (Fig. 3). In the same time, validated classiﬁ-
cation criteria may warrant the correct patient's selection for clinico-
therapeutical trials. Finally, the cooperation between multidisciplinary
groups with different experiences may be the next step for the consen-
sus study on the nomenclature and classiﬁcation criteria of still indeﬁn-
able variants of ILDs and CTDs [10,11].
The ILDs and CTDs represent two wide heterogeneous groups of dis-
orders in the ﬁelds of pneumology and rheumatology, respectively. The
ILDs may be correlated to a wide number of triggering factors or other
well-knowndiseases, in the absence of these conditions some individuals
are classiﬁed as having IPF [71]. Similarly, CTDs and other systemic auto-
immune rheumatic diseases may be complicated in variable percentage
by ILD [72,73] which is particularly frequent and severe in some condi-
tions such as systemic sclerosis (Table 5; 34,48–50), or uncommon,
often subclinical in others (see references in Table 5). Nevertheless, inter-
stitial pneumonia can be regarded as the intersection between ILDs and
CTDs; the different prevalence of this speciﬁc organ involvement in
CTDs, as well as of different CTD phenotypes, may be the results of a var-
iable combination of genetic and/or environmental etiopathogenetic co-
factors in individual patients. Likely, a comparable process can be as-
cribed to ILDs, especially to clinical variants with associated autoimmune
features suggestive of underlying CTDs [10,11].
This marked difference can be correlated to a clear-cut selection bias
in the patient's referral: those with clinically dominant respiratory
symptoms are invariably referred to tertiary pulmonary care unit,
while patients with a variable composition of autoimmune features
butwithout or subclinical respiratory symptoms are commonly referred
to the Rheumatology Care Center (Fig. 1). The three patients' series re-
ported in Table 3 constitute the spectrum of undifferentiated/unclassiﬁ-
able conditions that can be observed in the ﬁeld of ILDs or CTDs
commonly referred to our two tertiary care units (Fig. 2): from one
side there are patients without any possible cause of interstitial
69C. Ferri et al. / Autoimmunity Reviews 15 (2016) 61–70pneumonia such as environmental exposures or immune-mediated dis-
orders, i.e. U-ILD, from the opposite side there are the so-called UCTD,
while the IPAF may represent a transition between U-ILD and UCTD,
being characterized by the presence of both ILD and autoimmune
features not fulﬁlling the diagnosis of deﬁnite CTD [11]. While U-ILD re-
main stable after the initial patients' assessment, a number of patients
with IPAFmight develop overt ILD-CTD; similarly, themajority of stable
UCTD represent a durable condition during the time. However, both
IPAF and UCTD may be a prodromic condition or very early phase of a
given CTD; the evolution into deﬁnite CTD is more likely during the
ﬁrst years of follow-up. At the ﬁrst assessment and during the initial
follow-up period, it is important to identify patients with speciﬁc
clinico-serological characteristics suggestive of deﬁnite CTD, with im-
portant implications on the therapeutical strategies (Fig. 3).
The parceling of internal medicine into several specialties and sub-
specialties has been the natural consequence of the vast growing of
the medical knowledge during the last decades. At the same time,
there is an increasing needing in the clinical practice of rediscovery
the ‘whole’ and the interdependence of single components for a correct
patient's assessment andmanagement. The holistic approach is particu-
larly recommendable for patients with complex, multiorgan disorders
such as systemic autoimmune diseases, but also for apparently isolated
organ-speciﬁc diseases, among which the ILDs that not rarely may be
the presenting symptom of the above-mentioned systemic disorders.
Take-home messages
• Interstitial lung diseases (ILDs)may be associated to connective tissue
diseases (CTDs) or other systemic autoimmune diseases (AIDs).
• In some ‘autoimmune ﬂavored’ ILDs the possible underlying disorder
does not fulﬁll the classiﬁcation criteria of a given CTD.
• For these patients the term interstitial pneumonia with autoimmune
features (IPAF) has been recently proposed.
• IPAF share several clinico-serological features with undifferentiated
connective tissue diseases (UCTD), except for ILD that is rarely found
in UCTD.
• This difference might be due to pre-selection bias in the patient's re-
ferral depending on the presence/absence of clinically dominant ILD.
• Ourmodel of interdisciplinary pneumology–rheumatology evaluation
and management of IPAF/UCTD patients is proposed.References
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